Drug

Why Amgen’s Spending Billions to Buy This 1 Drug; Plus Heart Disease Has a New EnemyWhy Amgen’s Spending Billions to Buy This 1 Drug; Plus Heart Disease Has a New Enemy

After the Federal Trade Commission (FTC) demanded Bristol-Myers Squibb (NYSE:BMY) sell its blockbuster Otezla to secure approval for its $74 billion acquisition of Celgene (NASDAQ:CELG), a bidding war resulted in Amgen (NASDAQ:AMGN) agreeing